Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limertinib + radiotherapy
- Development stage
- Unknown
- Lead developer
- Jiangsu Aosaikang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Limertinib + radiotherapy is a combination therapeutic regimen being investigated for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases. Limertinib (ASK120067) is an orally bioavailable, third-generation, irreversible tyrosine kinase inhibitor (TKI) that selectively targets both EGFR-sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR. Developed by Jiangsu Aosaikang Pharmaceutical and Innovent Biologics, limertinib is designed with high central nervous system (CNS) penetration. Radiotherapy is used in conjunction with the TKI to provide local control of brain lesions, potentially acting synergistically to improve intracranial response rates and progression-free survival. This specific combination is currently being evaluated in a Phase II clinical trial led by The First Affiliated Hospital of Guangzhou Medical University.
- Other names
- ASK120067 + radiotherapyLimertinib Plus Radiotherapy
02
Targets
EGFR ex20ins (Epidermal growth factor receptor exon 20 mutant)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on limertinib + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limertinib + radiotherapy.